OncoLaB

Overview

Updated: Sep 16, 2026

Company Overview

ANGel is a hydrogel microparticle based precision formulation and delivery platform. It is designed to integrate multi antibody function (multi mechanism) and a payload driven drug effect (ADC like action) in a single dosage form, while staying compatible with existing therapeutic assets. Built for localized administration around the tumor site with a sustained release profile, ANGel is developed as a platform that can be standardized, reproduced, and transferred—not a one off formulation.

Address

Headquarters :Chungbuk Center for Creative Economy & Innovation, 194-25, Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea

Research Center :Room 842, Building BA, Hyundai Premier Campus, 380, Dongsan-dong, Deogyang-gu, Goyang-si, Gyeonggi-do, Republic of Korea

Website

https://oncolab.co.kr/ko/

Class

Pharmaceutical

Partnering Goals

Private

Investment Info

Investment History

Total USD 1M 72K

2024. 06.
71K
Investor Amount
CCEI-Chungbuk 71K
2024. 06.
143K
Investor Amount
Chungcheong Angel Bridge Fund 143K
2024. 11.
143K
2025.09
715K

Investor	Amount
CCEI-Chungbuk	71K

Investor	Amount
Chungcheong Angel Bridge Fund	143K

Shareholders

Jongseong Kim

Scalar Foxtrot Co., Ltd.

Doogie Oh and 1 additional investor

Chungbuk CCEI, Chungcheong Angel Bridge Fund, and BTB Ventures

Funding Goal

Target StageSeries A

Target Amount~3.6Million

Funding Purpose

Use of Funds - Product development and personnel costs - Sales and marketing - Clinical preparation (GLP, GMP, IND)

Team

Key People

CEO

Jongseong Kim

Ph.D. in Chemistry, Georgia Tech Former) Research Fellow, Harvard Medical School Present) Professor, Korea University

Director

Andrew Lyon

Former) Chair at Chemistry of Georgia Tech Present) Dean, Fowler School of Eng. Chapman Univ. Co-founder of Sanguina, LLC Co-founder of SelSym Biotechnology, Inc. Number of publications (>160), h -index 76 total citations ~20,000)

Director

Heejoo Cho

M.S. at Chemistry of Georgia Tec Former) Consultant, Ivy Prep (Boston) Former) Public Sector Experience, GoyangCity Government (Climate & Energy Division) Present) OncoLab: GLP/CMC and Business Development lead

PR

Yunjin Chae

M.S., Biological Sciences, Konkuk University Co-author, Advanced Healthcare Materials TNBC therapeutic composition patent ANGel preclinical lead

Director

Younggun Song

B.S., Electrical Engineering, Yonsei University Patent Attorney, Muhan IP Law Firm Patent Attorney, Kim & Chang ANGel preclinical lead Chair, Korea Patent Attorneys Association

Advisors

Private

Tech & Products

Technology Details

Local delivery to the tumor site

ANGel is administered by subcutaneous (SC) injection around the tumor site. Local delivery is the starting point of its design, intended to focus drug exposure on the tumor area and limit systemic exposure.

Combination by design without conjugation chemistry

Antibody combinations and small-molecule payloads are built into the ANGel design from the start. Antibodies are bound to the particle surface without conjugation chemistry, and binding has been confirmed for two distinct antibody types. A condition for loading two antibodies simultaneously has been validated, and small-molecule anticancer drugs are loaded inside the particle.

Sustained release from the administration site

ANGel provides a sustained exposure profile engineered through formulation and release design. In a luminescence-based biodistribution study, ANGel remained at the administration site for more than 60 days. The release rate can be adjusted through the drug loading composition, and the platform is designed to reduce dosing frequency.

Regulatory pathway and platform transferability

ANGel has been classified as a Class IV medical device in Korea, and GMP manufacturing and an exploratory first-in-human clinical study are in preparation. The platform is developed to be standardized, reproduced, and transferred across programs, with specifications, reproducibility, and CMC documentation being organized to support partner due diligence.

Problem & Unmet Needs

Unmet need in TNBC

Triple-negative breast cancer (TNBC) lacks estrogen and progesterone receptor expression and HER2 overexpression, so hormone therapy and conventional HER2-targeted therapy are not applicable. Treatment for TNBC includes combinations of immune checkpoint inhibitors and chemotherapy. The effect of such combinations depends not only on the drugs themselves but also on where exposure occurs, how long it lasts, and how the components act together.

Market Trends

Solid tumor immunotherapy market

The global immuno-oncology market is projected to reach approximately USD 357 billion by 2032, and the solid tumor therapeutics market approximately USD 307 billion by 2030, based on market research estimates. ANGel is developed for this market, starting with TNBC.

Shift toward platform technologies

Bispecific antibodies and antibody-drug conjugates (ADCs) have shown the value of combining multiple mechanisms and payload effects. The market is also shifting toward platform technologies that can be applied directly to existing pipelines to extend performance and lifecycle value. ANGel addresses this demand through a reformulation-first path. It implements multi-antibody function and payload effects through formulation, without new antibody engineering, and is designed to leverage approved or clinically validated assets.

Lifecycle value of existing antibody assets

As key immuno-oncology (IO) antibody patents approach expiration, pharmaceutical companies are seeking ways to extend the lifecycle value of existing assets. ANGel is structured for partnering through option, co-development, and licensing models, starting with TNBC and expanding into other hard-to-treat solid tumors.

Competitive Landscape

A formulation option alongside existing modalities

Antibody engineering, bispecific antibodies, and ADCs create new molecules. ANGel takes a different path by adding a formulation layer to existing antibodies and small-molecule drugs, combining them in a single hydrogel microparticle for localized, sustained delivery. ANGel can therefore be evaluated alongside a partner's existing programs as a parallel development option.

Preclinical efficacy and safety in TNBC models

In a syngeneic TNBC mouse model, loading the same drugs into ANGel improved tumor growth control compared with administering them in free form. In TNBC cell studies, ANGel loaded with immune checkpoint antibodies increased tumor cell killing compared with the antibodies alone, without significant toxicity to normal cells. GLP safety testing (11 items) has also been completed.

Pipeline

ANGel-TNBC02

Indication

Oncology

Modality

Antibodies

Sub-Modality

ADCs

Current Stage

IDE

CandidatePreclinicalIDEPhase 1Phase 2Phase 3NDA

Patents & Papers

Papers

Paper Title

Antibody-Conjugated Nanogel with Two Immune Checkpoint Inhibitors for Enhanced Cancer Immunotherapy

Journal

Advanced Healthcare Materials

Published Year

2024

PMID

38569198

Impact Factor

10

Patents

Patent Title

Pharmaceutical composition for the treatment of cancer

Status

Filed

Application Year

2024

Application Countries

KR

Patent Title

A pharmaceutical composition for the prevention or treatment of triple-negative breast cancer, comprising hydrogel particles containing multiple antibodies on their surface as an active ingredient

Status

Filed

Application Year

2024

Application Countries

KR

Patent Title

A method for manufacturing hydrogel particles with integrated process and quality controls

Status

Filed

Application Year

2026

Application Countries

KR

Patent Title

An anti-cancer drug delivery composition comprising hydrogel microparticles loaded with small molecule cytototoxic agent, and immune checkpoint inhibitor, and A method for preparing the same

Status

Filed

Application Year

2026

Application Countries

KR

Patent Title

항체 결합 단백질을 매개로 2종 이상의 항체가 표면 결합된 하이드로젤 입자 및 이를 포함하는 고형암 치료용 약학 조성물

Status

Filed

Application Year

2026

Application Countries

Private

Latest News

"세계 무대 도약"… 컴업스타즈 2026, 스타트업 최종 30개사 선발

Digital Chosun Inc

��ż��'4�� in �� '�� : ��Ʈ ��

Private

Overview

Company Overview

OncoLaB

Investment Info

Investment History

Shareholders

Funding Goal

Team

Key People

Advisors

Tech & Products

ANGel: hydrogel microparticle platform for local sustained release of antibodies and small molecules

Technology Details

Local delivery to the tumor site

Combination by design without conjugation chemistry

Sustained release from the administration site

Regulatory pathway and platform transferability

Problem & Unmet Needs

Unmet need in TNBC

Market Trends

Solid tumor immunotherapy market

Shift toward platform technologies

Lifecycle value of existing antibody assets

Competitive Landscape

A formulation option alongside existing modalities

Preclinical efficacy and safety in TNBC models

Pipeline

Patents & Papers

Papers

Patents

Latest News